XML 91 R80.htm IDEA: XBRL DOCUMENT v3.24.3
Segment Reporting - Reconciliation of Segment Profits to Income before Taxes (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Segment Reporting Information [Line Items]        
Profits $ 4,090 $ 5,620 $ 15,766 $ 3,935
Interest income 127 73 269 295
Interest expense (330) (317) (943) (836)
Amortization     (1,720) (1,582)
Depreciation     (1,582) (1,326)
Research and development (5,862) (3,307) (13,354) (20,904)
Restructuring costs (56) (126) (258) (344)
Operating Segments        
Segment Reporting Information [Line Items]        
Profits 12,057 10,828 35,225 30,853
Operating Segments | Pharmaceutical segment        
Segment Reporting Information [Line Items]        
Profits 11,547 10,407 33,651 29,400
Operating Segments | Animal Health segment        
Segment Reporting Information [Line Items]        
Profits 510 421 1,574 1,453
Corporate, Non-Segment        
Segment Reporting Information [Line Items]        
Profits 117 190 391 374
Interest income 127 73 269 295
Interest expense (330) (317) (943) (836)
Amortization (633) (562) (1,720) (1,582)
Depreciation (467) (401) (1,368) (1,175)
Research and development (5,716) (3,183) (12,926) (20,523)
Restructuring costs (56) (126) (258) (344)
Charge for Zetia antitrust litigation settlements 0 0 0 (573)
Other unallocated, net $ (1,009) $ (882) $ (2,904) $ (2,554)